A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma

NCT02129075 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

NIH

Sponsor class

Conditions

Cutaneous Melanoma
Melanoma
Melanoma of Unknown Primary
Mucosal Melanoma
Ocular Melanoma
Stage IIB Cutaneous Melanoma AJCC v6 and v7
Stage IIC Cutaneous Melanoma AJCC v6 and v7
Stage III Cutaneous Melanoma AJCC v7
Stage IIIA Cutaneous Melanoma AJCC v7
Stage IIIB Cutaneous Melanoma AJCC v7
Stage IIIC Cutaneous Melanoma AJCC v7
Stage IV Cutaneous Melanoma AJCC v6 and v7

Interventions

BIOLOGICAL: DEC-205/NY-ESO-1 Fusion Protein CDX-1401
DRUG: Poly ICLC
BIOLOGICAL: Recombinant Flt3 Ligand

Sponsor

National Cancer Institute (NCI)